Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study consists of Lp(a) measurement and additional screening assessments, a double-blind treatment period of 18 months, and a 16-week safety follow up period from the last dose. Efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo will be assessed throughout the study, with primary analysis at Day 180 and final analysis at Day 540.
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Lp(a) ≥ 150 nmol/L
Within 10 days of hospitalization for ACS event and meets all of the following criteria:
Clinical syndrome consistent with spontaneous cardiac ischemia
Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)
You may not be if
Uncontrolled hypertension
Heart failure New York Heart Association (NYHA) class IV
History of malignancy of any organs
History of hemorrhagic stroke or other major bleeding
Platelet count ≤ LLN
Active liver disease or hepatic dysfunction
Significant kidney disease
Contraindication for CCTA or severe contrast allergy